Clinical Trial Update: ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy

View source ↗

Summary

A clinical trial comparing indocyanine green (ICG) versus patent blue dye for targeted axillary dissection in clinically node-positive breast cancer after neoad…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Blue Patent (patent blue dye (isosulfan blue))
• Indocyanine Green (Indocyanine Green)

Snippet

Sponsor: Hospital Universitari de Bellvitge | Conditions: Breast Cancer, Axillary Metastases | Status: RECRUITING